Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update

During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio's relative performance in the quarter were nLight, Terawulf, and BWX Technologies.

Seeking Alpha • Oct 15, 2026

How to Invest in AI Drug Discovery

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

ETF Trends • Oct 14, 2026

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Moderna's stock has skyrocketed on exciting results from its personalized cancer vaccine. Twist Bioscience's synthetic DNA is enjoying strong demand.

The Motley Fool • Oct 12, 2026

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

ETF Trends • Sep 30, 2026

Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?

Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.

Benzinga • Sep 25, 2026

3 Analysts, 3 Trades to Make Today

On any given day, there's a headline, a fear, or a worry screaming for your attention. We regularly cover those headlines here, doing our best to separate the signal from the noise so you can keep moving toward your financial goals.

InvestorPlace • Sep 22, 2026

Why Twist Bioscience Stock Skyrocketed This Week

The biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.

The Motley Fool • Sep 18, 2026

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan.

Business Wire • Sep 16, 2026

LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday.

Benzinga • Sep 16, 2026

Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem

Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).

Benzinga • Sep 16, 2026